Price T Rowe Associates Inc. MD Grows Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Price T Rowe Associates Inc. MD increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,036,412 shares of the biopharmaceutical company's stock after acquiring an additional 107,350 shares during the period. Price T Rowe Associates Inc. MD owned about 5.77% of Xencor worth $92,758,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,040 shares during the last quarter. GAMMA Investing LLC raised its position in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 508 shares during the period. KBC Group NV boosted its stake in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 813 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,337 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its position in shares of Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 1,282 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wedbush reiterated an "outperform" rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday. Wells Fargo & Company lowered their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, William Blair started coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.86.

Xencor Price Performance

XNCR stock traded up $0.40 during midday trading on Friday, hitting $11.26. The company's stock had a trading volume of 1,057,567 shares, compared to its average volume of 621,441. The firm has a market capitalization of $801.17 million, a price-to-earnings ratio of -3.52 and a beta of 0.99. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The company has a 50 day moving average of $11.31 and a two-hundred day moving average of $18.07.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to analysts' expectations of $17.14 million. On average, analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.